Evidence map›Paper›PMID 37547069›Full record

ReviewJACC. Basic to translational science2023

Immunometabolism at the Heart of Cardiovascular Disease.

Matthew DeBerge, Rajesh Chaudhary, Samantha Schroth, Edward B Thorp

Abstract readReview
In one paragraph

Review in JACC. Basic to translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Immunometabolic Remodeling in Ischemic and Non-Ischemic Heart Failure.Journal of cardiovascular translational research · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Immunometabolism in heart failure.Nature reviews. Cardiology · 2025
    Review
  15. Article
  16. Review
  17. The Cardiohepatic Axis in Metabolic Disease: Liver to Heart.JACC. Basic to translational science · 2025
    Review
  18. Multifaceted roles of neutrophils in cardiac disease.Journal of leukocyte biology · 2025
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matthew DeBergeDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Rajesh ChaudharyDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Samantha SchrothDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Edward B ThorpDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Funding

Efferocytosis-Directed Inflammation Resolution and Repair in the Hypoxic HeartR01HL122309 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI THORP, EDWARD BENJAMIN · 2014 to 2024
$5.0M
Contributions of Myeloid Metabolism to Diastolic DysfunctionR01HL159964 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI THORP, EDWARD BENJAMIN · 2022 to 2024
$1.5M
NHLBI NIH HHS R01 HL122309NHLBI NIH HHS R01 HL159964
6 · The paper itself

Abstract

Immune cell function among the myocardium, now more than ever, is appreciated to regulate cardiac function and pathophysiology. This is the case for both innate immunity, which includes neutrophils, monocytes, dendritic cells, and macrophages, as well as adaptive immunity, which includes T cells and B cells. This function is fueled by cell-intrinsic shifts in metabolism, such as glycolysis and oxidative phosphorylation, as well as metabolite availability, which originates from the surrounding extracellular milieu and varies during ischemia and metabolic syndrome. Immune cell crosstalk with cardiac parenchymal cells, such as cardiomyocytes and fibroblasts, is also regulated by complex cellular metabolic circuits. Although our understanding of immunometabolism has advanced rapidly over the past decade, in part through valuable insights made in cultured cells, there remains much to learn about contributions of in vivo immunometabolism and directly within the myocardium. Insight into such fundamental cell and molecular mechanisms holds potential to inform interventions that shift the balance of immunometabolism from maladaptive to cardioprotective and potentially even regenerative. Herein, we review our current working understanding of immunometabolism, specifically in the settings of sterile ischemic cardiac injury or cardiometabolic disease, both of which contribute to the onset of heart failure. We also discuss current gaps in knowledge in this context and therapeutic implications.

Indexed as

heart failureimmunometabolismmyocardial infarction

Identifiers

PMID37547069
PMCPMC10401297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.